Prota Publishes Long-Term Peanut Allergy Study In Allergy Journal
14 Aug 2024 //
PR NEWSWIRE
Prota CEO Mimi Tang Honored at BioMelbourne Women in Leadership Awards
29 Apr 2024 //
PR NEWSWIRE
Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
16 Jan 2024 //
ACCESSWIRE
Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate
16 May 2022 //
PRNEWSWIRE